Dose-tailoring of FEC adjuvant chemotherapy based on @entity1431 is feasible and well tolerated. XXXX and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.

@entity1 @entity1665 @entity137 @entity390 @entity0 @entity1259 @entity786 @entity391 @entity1431 @entity1487
The SBG 2000-1 trial is a randomised study that investigates if dose-tailored adjuvant FEC therapy based on the individual's leukocyte nadir value can improve outcome. The study has included 1535 @entity1 with medium and high-risk @entity0 . @entity1 AND METHODS: After a first standard dosed FEC course (5- @entity1487 600 mg/m(2), @entity1259 60 mg/mg(2) and @entity786 600 mg/m(2)), @entity1 who did not reach @entity1431 grade III or IV were randomised to standard doses (group standard) or doses tailored to achieve @entity1431 (group tailored) at courses 2-7. @entity1 who achieved @entity1431 grade III or more after the first course were not randomised but continued on standard doses (group registered). RESULTS: Both planned and actually delivered number of courses (seven) were the same in all three arms. The relative dose intensity was increased by a factor of 1.31 (E 1.22, C 1.43) for @entity1 in the tailored arm compared to the expected on standard dose. Ninety percent of the @entity1 in the tailored arm achieved @entity1431 grade III-IV compared with 29% among @entity1 randomised to standard dosed therapy. Dose tailoring was associated with acceptable acute non-haematological @entity137 with more @entity1665 , @entity390 , @entity391 and fatigue. CONCLUSION: Dose tailoring according to @entity1431 was feasible. It led to an increased dose intensity and was associated with acceptable excess of acute non-haematological @entity137 .
